Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18-Month Randomized Double-Blind Placebo-Controlled Study of LMTM in Mild Alzheimer's Disease
2012-002847-28Phase 3Completed
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing LMTM (TRx0237) with Placebo (2 arms). Primary endpoint: Co-primary clinical efficacy endpoints. Started Nov 2012; status: completed.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2012-002847-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002847-28.